1. Home
  2. WWR vs PMN Comparison

WWR vs PMN Comparison

Compare WWR & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WWR

Westwater Resources Inc.

HOLD

Current Price

$0.58

Market Cap

74.3M

ML Signal

HOLD

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

HOLD

Current Price

$13.40

Market Cap

131.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WWR
PMN
Founded
1977
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Metal Mining
Pharmaceuticals and Biotechnology
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.3M
131.5M
IPO Year
2006
2022

Fundamental Metrics

Financial Performance
Metric
WWR
PMN
Price
$0.58
$13.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$1.92
$42.67
AVG Volume (30 Days)
1.5M
31.2K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.38
$0.29
52 Week High
$3.75
$27.40

Technical Indicators

Market Signals
Indicator
WWR
PMN
Relative Strength Index (RSI) 52.90 46.88
Support Level $0.56 $12.89
Resistance Level $0.63 $14.77
Average True Range (ATR) 0.03 1.22
MACD -0.01 -0.13
Stochastic Oscillator 40.18 32.81

Price Performance

Historical Comparison
WWR
PMN

About WWR Westwater Resources Inc.

Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Share on Social Networks: